Neonatal HIV Early Infant Diagnosis (EID) Versus Standard of Care EID- Long Term Impact on inFant hEalth (LIFE)
NCT ID: NCT04032522
Last Updated: 2024-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6602 participants
OBSERVATIONAL
2019-10-23
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Point-of-Care EID for HIV-Exposed Infants
NCT03824067
HIV Point-of-Care Test Evaluation in Infants
NCT02545296
Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe
NCT04206241
Increasing Neonatal HIV Test and Treat to Maximize the Long-Term Impact on Infant Health and Novel Infant Antiretroviral Treatment
NCT06267508
Early Infant Diagnosis Point of Care Pilot
NCT02634450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm (A)
Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA \>1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
point-of care (PoC) neonatal HIV early infant diagnosis (EID)
clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
Control Arm (B)
The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
point-of care (PoC) neonatal HIV early infant diagnosis (EID)
clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Voluntary and informed consent of the legal guardian of the child for participation of the child in the study.
3. Mothers/legal guardians ≥18 years of age.
4. Documented maternal HIV infection.
5. Willingness to consent to HIV testing for the child and herself.
6. Willingness to consent to active tracing including home tracing.
Exclusion Criteria
2. Having delivered more than 72h (3 days) ago
3. Prisoners
4. Women presenting with an emergency requiring immediate medical assistance if not resolved at study inclusion
5. Stillbirths
6. Infant requiring emergency care (e.g. immediate or rapid occurring life threatening conditions, resuscitation, prolonged obstetric related intensive care, severe jaundice) or born with severe malformation.
7. If within the discretion of the investigator based on recommendation of the gynaecologist or paediatrician in charge study participation would possibly add not acceptable risk or burden to the mother or infant (e.g. significant congenital malformation, health deficiencies, very low birth weight less than 1500g)
8. Unlikely to comply with protocol as judged by the principal investigator or his designate
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Saúde, Mozambique
OTHER_GOV
NIMR- Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
UNKNOWN
University of Lisbon Instituto Universitário Egas Moniz (IUEM) Lisbon, Portugal
UNKNOWN
Clinton Health Access Initiative Inc.
OTHER
Michael Hoelscher
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Hoelscher
Director, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arne Kroidl, Dr. med
Role: STUDY_CHAIR
Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich
Ilesh Jani, Dr., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Saúde, Mozambique
Issa Sabi, Dr.
Role: PRINCIPAL_INVESTIGATOR
NIMR- Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro de Investigacao Operacional da Beira (CIOB)
Beira, Sofala, Mozambique
Mbeya Medical Research Centre
Mbeya, , Tanzania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jani IV, Sabi I, Elsbernd K, Meggi B, Mahumane A, Lwilla AF, Pereira K, Boniface S, Edom R, Lequechane J, Chale F, Chiwerengo N, Ntinginya NE, Mudenyanga C, Mueller M, Rauscher M, Hoelscher M, Taveira N, Buck WC, Kroidl A; LIFE Study Consortium. Impact of Point-of-Care Birth Test-and-Treat on Clinical Outcomes Among Infants With HIV: A Cluster-Randomized Trial in Mozambique and Tanzania. Clin Infect Dis. 2025 Jun 4;80(5):1114-1124. doi: 10.1093/cid/ciae530.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMU-IMPH-LIFE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.